Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists hunt for food clues in blood and urine

NCT ID NCT05580653

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked for chemicals in blood and urine that can show what foods people have eaten, like beef, beans, and eggs. Thirty healthy adults ate controlled meals and gave samples over several days. The goal is to develop more accurate ways to measure diet than asking people to remember what they ate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Mar 2023

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Healthy adults 2. Age 18 years and older 3. Willing to come to the Fred Hutch campus 16 times during the study 4. BMI 18.5-39.9 kg/m2 Exclusion Criteria: 1. History of gastrointestinal disorders (e.g., ulcerative colitis, Crohn disease, celiac sprue, Hereditary Non-polyposis Colorectal Cancer, familial adenomatous polyposis, pancreatic disease, liver disease) 2. Bleeding disorder that precludes blood draws 3. Previous gastrointestinal resection or bariatric surgery 4. Recent hospital admissions (in past 6 months) for heart disease (myocardial Infarction/cerebrovascular accident or congestive heart failure) or other cardiovascular disease/coronary artery disease condition under physician guided therapy that is not medically stable. 5. Cancer under active radiation or chemotherapy treatment (post-6 mos) 6. Pregnant or lactating 7. Weight change (±5% in 3 months) 8. Regular alcohol intake of \>2 drinks/day (2 drinks being equivalent to 720 ml beer, 240 ml wine, or 90 ml spirits) and unwilling to abstain during feeding periods 9. Use of tobacco and/or marijuana, hookahs, e-cigarettes (e-cigs, vaping devices, etc) and not willing to abstain during feeding periods. 10. Use of illicit drugs and not willing to abstain during feeding periods. 11. BMI ≥40 kg/m2 12. Seated blood pressure \> 140/90 mm Hg 13. Fasting clinical lab tests outside acceptable value as ascertained at a screening blood draw° 14. Food allergies/intolerances or major dislikes to foods used in the study menus; unwilling to consume study foods. 15. Current use of specific prescription medication (study staff will review medications to determine eligibility)\*\* 16. Regular (daily to weekly) use of over-the-counter weight-loss aids, anti-inflammatories, and unable to stop taking these during feeding periods 17. Unwilling to stop taking OTC dietary supplements that interfere with the test foods being studied, including pills, chewables, liquids or powders for the following: protein supplements, soy, fiber, flaxseed, fish oil (incl. cod liver oil), probiotics, glucosamine and chondroitin (if vitamin supplement is MD prescribed - may continue). Study staff will review supplements to determine eligibility 18. Oral or IV antibiotic use in the past 3 months (could defer participation until 3 months post completion of course of antibiotics) 19. Inability to freely give informed consent. * Fasting clinical lab tests outside acceptable value as ascertained at a screening blood draw: Description \[Acceptable Values\] Glucose-Fasting: Serum Glucose \[54-125 mg/dl\] Urea: BUN \[6-50mg/dl\] Serum Creatinine \[0.4-1.3 mg/dl\] eGFR: estimated GFR \[\>60ml/min\] Serum Sodium \[133-146 mmol/L\] ALT/GPT Liver Enzyme \[5-60 U/L\] AST/GOT Liver Enzyme \[5-40 U/L\] Alkaline Phosphatase Liver Enzyme \[20-135 U/L\] Total Bilirubin Liver Function \[0.0-1.9 mg/dl\] Total Serum Protein \[5-9.0 g/dl\] Albumin Serum Protein \[3.5-5.9 g/dl\] LDL Cholesterol \[\<160 mg/dl\] Triglycerides \[\<500 mg/dl\] WBC White Blood Cells \[3-10.5 K/uL\] HCT (women) Hematocrit \[35-48 g/dl\] HCT (men) Hematocrit \[37.5-49 g/dl\] \*\*Medication use for exclusion: 1. Diuretics 2. Steroids (oral): daily oral any dose within 1 month of study, except OCP as noted below 3. Opiates: any use within 1 month of study 4. Anti-lipid medications that affect GI or renal function (ie. Fibrates) 5. Hyperglycemia medications other than metformin (ie. insulin, SGLT2 inhibitor, α-glucosidase inhibitor) 6. Psychiatric that affect metabolism/renal function (anti-psychotics, lithium) 7. Biologic/immune modulators (ie. RA, psoriasis, other rheumatologic/hematologic active disease) 8. Anti-coagulants (coumadin, heparin, Eliquis, etc.) 9. HIV/HAART, etc. (dyslipidemic)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy adults are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.